Cost Recovery Implementation Statement (CRIS) - Regulation of medicinal cannabis 2020-21
Learn how cost recovery supported the regulation of Australia's Medicinal Cannabis Scheme in 2020–21, including fees, performance reporting and financial forecasts.
About this statement
The Cost Recovery Implementation Statement (CRIS) explains how the Department of Health implemented cost recovery for regulatory activities associated with the Medicinal Cannabis Scheme.
The statement provides transparency about the costs of regulating the scheme and how those costs are recovered from businesses and organisations that participate in regulated activities.
Cost Recovery for Medicinal Cannabis Regulation
Cost recovery allows government agencies to recover some or all of the efficient costs associated with regulatory activities. This may include charges such as:
- application fees
- annual charges
- other regulatory fees and levies.
These arrangements support the administration of the Medicinal Cannabis Scheme under the Narcotic Drugs Act 1967.
Financial and performance reporting
The CRIS includes:
- financial performance information
- non-financial performance information
- cost recovery arrangements for medicinal cannabis regulation
- financial forecasts for 2020–21, 2021–22 and the following three financial years.
The statement is maintained while cost recovery arrangements for the activity remain in place.